Source: Annual Congress 2005 - Biological and molecular features in lung cancer
Disease area: Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
K. C. Shin, J. H. Chung, K. H. Lee, H. J. Park, C. H. Jeon, J. W. Park (Daegu, Gumi, Republic Of Korea). p53 gene mutations in lung cancer in Korean. Eur Respir J 2005; 26: Suppl. 49, 2152

Member's Comments

No comment yet.

Related content which might interest you: The analysis of CHEK2 gene mutation in small cell lung cancer Source: Virtual Congress 2021 – Novel insights into the pathogenesis of chronic lung diseases Year: 2021 Arg72Pro P53 gene polymorphism is associated with P53 mutations in non-small cell lung cancer (NSCLC) patients Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Characteristics and prognostic relevance of p53 gene mutations in Polish non small cell lung cancer (NSCLC) patients Source: Eur Respir J 2005; 26: Suppl. 49, 92s Year: 2005 The correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance Source: Annual Congress 2005 - Prognostic factors in lung cancer Year: 2005 Polymorphism in GSTM1, GSTT1, p53 and CCR5 genes and lung cancer progression: relation to p53 and Ki-67 protein expression in tumors of non-small cell lung cancer patients Source: Eur Respir J 2006; 28: Suppl. 50, 810s Year: 2006 Clinical relevance of p53 and K-ras mutations in nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001 Prognostic value of TP53, KRAS and EGFR mutations in nonsmall cell lung cancer: the EUELC cohort Source: Eur Respir J 2012; 40: 177-184 Year: 2012 Association of polymorphism of the human nm23-H1 gene (NME1) with susceptibility to and severity of non-small cell lung cancer Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology Year: 2007 Concordance of p53 and K-ras mutations in induced sputum and corresponding biopsies of patients with nonsmall cell lung cancer (NSCLC) Source: Eur Respir J 2001; 18: Suppl. 33, 18s Year: 2001 Clinical relevance of p53 and K-ras gene mutations in bronchial margins in surgically treated nonsmall cell lung cancer (NSCLC) patients Source: Eur Respir J 2002; 20: Suppl. 38, 230s Year: 2002 Croatian Caucasians with lung adenocarcinoma harbouring EGFR mutations with and without brain metastasis Source: International Congress 2017 – Lung cancer: clinically relevant aspects of epidemiology, co-morbidities, metastasised disease and follow-up Year: 2017 K-RAS oncogenic mutations in patients with nonsmall cell lung cancer Source: Annual Congress 2007 - Biology of thoracic malignancies Year: 2007 Polymorphisms A1026G and G369C of CDKN1A/p21 and p53 genes in lung cancer Source: Annual Congress 2011 - Lung cancer: molecular pathology and functional genomics Year: 2011 Association of -93G®A polymorphism in the hMLH1 gene with susceptibility to and prognosis of non-small cell lung cancer in Taiwan Source: Eur Respir J 2006; 28: Suppl. 50, 151s Year: 2006 Arg72Pro P53 gene polymorphism as a predisposing factor for non-small cell lung cancer (NSCLC) development Source: Eur Respir J 2004; 24: Suppl. 48, 78s Year: 2004 Germ-line exon 21 EGFR mutations, V843I and P848L, in nonsmall cell lung cancer patients Source: Eur Respir Rev 2014; 23: 390-392 Year: 2014 Evaluation of EGFR mutations and ERCC2 polymorphisms in treatment of non-small cell lung cancer Source: Annual Congress 2005 - Chemotherapy and palliative care Year: 2005 Investigation of survivin gene polymorphism in non-small cell lung cancer patients (NSCLC) Source: Annual Congress 2012 - New biomarkers for lung cancer Year: 2012 p53 and mdm2 expression in nonsmall cell lung cancer (NSCLC): the lack of prognostic relevance Source: Eur Respir J 2001; 18: Suppl. 33, 230s Year: 2001